Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fed Conditions

This study has been completed.
Sponsor:
Information provided by:
Dr. Reddy's Laboratories Limited
ClinicalTrials.gov Identifier:
NCT01164800
First received: July 16, 2010
Last updated: NA
Last verified: July 2010
History: No changes posted
  Purpose

The purpose of this study is

  • To compare the single oral dose bioavailability of test product, Trandolapril 4 mg Tablets of Dr. Reddy's and Mavik® 4 mg Tablet of Abbott Laboratories, in healthy, adult, human subjects, under fed conditions to assess bioequivalence.
  • To monitor adverse events and ensure safety of subjects.

Condition Intervention Phase
Healthy
Drug: Trandolapril
Drug: Mavik
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Comparative Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited and Mavik® 4 mg Tablets of Abbott Laboratories, in Healthy, Adult, Human Subjects Under Fed Conditions

Resource links provided by NLM:


Further study details as provided by Dr. Reddy's Laboratories Limited:

Primary Outcome Measures:
  • Bioequivalence is based on Cmax and AUC parameters. [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Enrollment: 52
Study Start Date: March 2006
Study Completion Date: May 2006
Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Trandolapril
Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
Drug: Trandolapril
Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
Other Name: Mavik® 4 mg Tablets
Active Comparator: Mavik®
Mavik® 4 mg Tablets of Abbott Laboratories, USA.
Drug: Mavik
Mavik® 4 mg Tablets of Abbott Laboratories, USA.

Detailed Description:

An open label, randomised, two-treatment, two-sequence, two-period, two-way cross-over,single-dose bioequivalence study of Trandolapril4 mg Tablets manufactured by Dr. Reddy's Laboratories Ltd., Generics, India comparing with the Mavik® 4 mg Tablets (containing trandolapril 4 mg) manufactured by Abbott Laboratories, North Chicago, IL 60064, US; in healthy, adult, human subjects under fed conditions with a wash out period of 30 days between two periods.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy human subjects within the age range of 18 to 45 years
  • Non-smokers since at least six months
  • Willingness to provide written informed consent to participate in the study
  • Body-mass index of ≥ 18.5 kg/m2 and ≤24.9 kg/m2, with body weight not less than 50 kg
  • Absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluations, medical history or physical examination during the screening Normal 12-lead ECG or one with abnormality considered to be clinically insignificant Normal chest X-ray PA view Comprehension of the nature and purpose of the study and compliance with the requirement of the Protocol
  • Female Subjects

    • of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm,intrauterine device (IUD), or abstinence, or
    • postmenopausal for at least 1 year, or
    • surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject

Exclusion Criteria:

  • Personal/family history of allergy or hypersensitivity to Trandolapril or allied drugs
  • Past history of anaphylaxis or angioedema
  • Any major illness in the past three months or any clinically significant ongoing chronic medical illness e.g. congestive heart failure, hepatitis, pancreatitis etc.
  • Presence of any clinically significCint abnormal values during screening e.g. significant abnormality of Liver Function Test (LFT), Renal (kidney) Function Test (RFT), etc.
  • Any cardiac, renal or liver impairment, any other organ or system impairment
  • History of seizure or psychiatric disorders
  • Presence of disease markers of HIV 1 and 2, and hepatitis B and C virus
  • Consumption of alcohol for more than two years, or consumption of more than three alcoholic drinks per day or consumption of alcohol within 48 hours prior to dosing and during the study [one drink is equal to one unit of alcohol [one glass wine, half pint beer, and one measure (one ounce) of spirit).
  • Consumption of xanthine containing derivatives (coffee, tea, cola drinks, chocolate) within 48 hours before check-in of each period
  • Use of any recreational drug or a history of drug addiction
  • Participation in any clinical trial within the past 3 months
  • Inaccessibility of veins in left and right arm
  • Donation of blood (one unit or 350 mL) within 3 months prior to receiVing the first dose of study medication
  • Regular smoker who has a habit of smoking more than nine cigarettes per day and has difficulty in abstaining from smoking from 48 hours before dosing and until the completion of the study.
  • Receipt of any prescription drug therapy within four weeks or over-the-counter (OTC) drugs within two weeks prior to receiving the first dose of study medication or repeated use of drugs within the last four weeks
  • An unusual diet, for whatever reason e.g. low sodium diet, for two weeks prior to receiving any medication and through out subject's participation in the study
  • Consumption of grapefruit- containing food or beverages within 10 days prior to receiving the first dose of study medication in both the periods
  • Recent history of dehydration from diarrhoea, vomiting or any other reason within a period of 24 hours prior to the study
  • Female subjects who are pregnant or who are able (women with child bearing potential) to become pregnant during the study will not be allowed to participate.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01164800

Locations
India
Wellquest Clinical Research
Mumbai, Maharashtra, India, 400013
Sponsors and Collaborators
Dr. Reddy's Laboratories Limited
Investigators
Principal Investigator: Dr. Umesh Dhakate, M.B.B.S Wellquest Clinical Research
  More Information

No publications provided

Responsible Party: Mr. M.S. Mohan/ Vice President R & D, Dr. Reddy's Laboratories Limited
ClinicalTrials.gov Identifier: NCT01164800     History of Changes
Other Study ID Numbers: CL-029-TRAN-2006
Study First Received: July 16, 2010
Last Updated: July 16, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Dr. Reddy's Laboratories Limited:
Bioequivalence
Crossover
Trandolapril

Additional relevant MeSH terms:
Trandolapril
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Cardiovascular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on November 27, 2014